EmeraMed: Targeting the cause of diseases.
Emeramide is a lipophilic compound that crosses the blood-brain barrier and is intracellularly accessible. It is currently under FDA review as a treatment for mercury poisoning.
- COPD: A Phase 2a clinical trial evaluating Emeramide in patients with COPD was completed in 2018. The study found Emeramide to be well-tolerated, with no serious adverse events reported.
- Other conditions: Preclinical studies on Emeramide have been conducted for various other potential applications. Additional clinical research is ongoing or planned.
Latest Information
Emeramide (NBMI): Mercury Chelator Under FDA Review
Emeramide (Also known as Irminix®) is a lipophilic mercury chelator in development by EmeraMed, that is currently under FDA review as a treatment for mercury poisoning.
Warning: Counterfeit Emeramide sold illegally in EU & USA
Counterfeit Emeramide is being sold under our various trade names (OSR#1, NBMI, Emeramide) and tests have shown that it is not Emeramide. This is unsafe and illegal and we are continuously in contact with various regulatory authorities to take action.
Pilot Study Results: Emeramide (NBMI) in Mercury-Exposed Gold Miners in Zaruma Ecuador
Discover results from a pilot study of NBMI (Emeramide) in mercury-exposed gold miners in Zaruma, Ecuador. The 300 mg/day group showed significant reduction in physical fatigue and promising improvements in symptoms and urinary mercury levels despite ongoing exposure.
